Gilead Sciences (Nasdaq: GILD) announced that the U.S. Food and Drug Administration has approved Trodelvy (sacituzumab govitecan-hziy) for the first-line ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA